Remove Community Remove Family Remove Government Remove Manufacturing
article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law

Koblitz — You know a court decision is going to be worth reading when the judges compare FDA’s regulatory governance of flavored e-cigarettes to a Shakespearean gaslighting. FDA extended PMTA compliance deadlines for years so it could figure out appropriate application instructions and so that manufacturers could figure out how to comply.

article thumbnail

Baby Formula Shortages

Georgetown Pediatrics & Family Medicine

If not, your pediatrician’s office can work with you to access all community resources. Always mix formula as directed by the manufacturer. I heard the government will be importing baby formula from other countries. The post Baby Formula Shortages appeared first on Georgetown Pediatrics & Family Medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gabapentinoids – Gabapentin and Pregabalin: Tasce Bongiovanni, Donovan Maust and Nisha Iyer

GeriPal

And for that reason, there was actually an enormous lawsuit, and the manufacturer was fined, now I think 20 years ago, in the millions and millions of dollars for off-label prescribing. These are families who are in distress. Eric: Although pregabalin, right, more misuse of pregabalin out in the community. Is that right?

article thumbnail

Aging and Climate Change: Karl Pillemer, Leslie Wharton, & Ruth McDermott-Levy

GeriPal

Leslie Wharton is a leader in the 26,000 member grassroots organization Elders Climate Action , which organizes older adults to create communities engaged in making a difference at local, state, and national levels. But Ruth, I was wondering too, and you invited us to ask each other questions, so my golly I’m going to do it.

article thumbnail

Gun Violence Reduction Law Further Extends Moratorium on Trump-Era Rebate Rule

FDA Law

If and when implemented, the amendments will likely force Medicare Part D plans and their PBMs to pass drug manufacturer rebates through to pharmacies to reduce out-of-pocket expenses of Part D enrollees, which would be a dramatic change from current practice.

Finance 52